Financial Data and Key Metrics Changes - Revenues for Q4 2025 were $4.9 million, a decrease from $31 million in Q4 2024, primarily due to lower unit sales [13] - Full year revenues for 2025 were $27.5 million, down from $41.8 million in 2024, driven by reduced sales to the largest customer [16] - Gross profit for Q4 2025 was $1.9 million, or 38.8% of revenues, compared to $7.1 million, or 54.2% in Q4 2024 [14] - Net loss for Q4 2025 was $3.2 million, or a loss of $0.19 per share, compared to net income of $1.5 million, or $0.09 per diluted share in Q4 2024 [15] - Full year net loss for 2025 was $7.7 million, or a loss of $0.47 per share, compared to net income of $6.6 million, or $0.41 per diluted share in 2024 [18] Business Line Data and Key Metrics Changes - The company shipped 14 units in Q4 2025, with 8 in the U.S. and 6 internationally, with no sales to the largest customer [5][22] - Utilization across the Fair Deal Agreement program increased substantially, with treatments up more than eightfold year-over-year and the number of patients treated increasing by over 250% [6] Market Data and Key Metrics Changes - International sales were strong in Q4 2025, with shipments to China and a growing demand in Asia, particularly in Taiwan and South Korea [7][28] - The company expects international markets to remain a significant part of its growth strategy, with Brazil clearance anticipated in 2026 [28] Company Strategy and Development Direction - The introduction of new CPT codes for SRT and IG-SRT technology is expected to enhance physician reimbursement and support broader adoption [4][20] - The company aims to achieve full-year profitability in 2026, supported by a diversified customer base and expanding international opportunities [8][19] - A disciplined approach to scaling the sales organization is being implemented, with plans to hire additional sales representatives [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with greater clarity and control over the business, emphasizing the positive impact of new reimbursement codes [20] - The company is focused on educating physicians about the new reimbursement codes to drive adoption and growth [5][8] Other Important Information - The company ended 2025 with $22.1 million in cash and cash equivalents, unchanged from the previous year, and no outstanding debt [18] - Research and development expenses for 2025 increased to $7.8 million, primarily due to higher costs related to billing and reimbursement efforts [17] Q&A Session Summary Question: Guidance on revenue growth excluding the largest customer - Management confirmed that projections for 2026 do not include expectations from the largest customer, as they are reevaluating their model moving forward [22][23] Question: Update on TDI and FDA approval - Management indicated ongoing efforts with the FDA regarding TDI but could not provide a timeline for approval [25] Question: International demand outlook - Management highlighted strong demand in China and growth in Taiwan, with expectations for further expansion in Asia and South America [27][28] Question: Reaction to reimbursement and system mix - Management noted a shift towards outright purchases and leasing options due to improved reimbursement clarity, with a stronger focus on SRT technology [37][41] Question: Interest from private equity-backed groups - Increased interest from private equity groups was noted, with a reevaluation of acquisition strategies due to clearer reimbursement pathways [42]